Prostate Cancer Clinical Trial

This video provides an overview of a new study for men with prostate cancer who want to avoid treatment through active surveillance. The study aims to determine if including PSMA PET scans improves the accuracy of detecting aggressive prostate cancer in patients on active surveillance. Participants will undergo standard tests like PSA, biopsy, and MRI, as well as PSMA PET scans before biopsy. The primary benefit of joining this trial is aiding future patients on active surveillance by providing more precise information about their cancer.

‍

Patients can participate if they are/have:

• Males aged ≥ 18
• Histologically confirmed low or favorable intermediate risk prostate cancer per NCCN guidelines. (Note: Grade Group 2 must have 20% or less involvement in every core and no presence of cribiform or intraductal carcinoma)
• PSA < 20 ng/ml
• Ability to undergo yearly PSMA-PET CT
• Ability to undergo yearly prostate mpMRI
• Ability to undergo transrectal or transperineal template and fusion prostate biopsy
• Ability to complete HRQOL surveys (EPIC, IPSS, IIEF-5)
• Willingness to undergo yearly prostate biopsies

‍